NeoCOAST-25 min read
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2
Patients with resectable non-small cell lung cancer (NSCLC) remain at high risk of relapse despite perioperative treatment1-3. NeoCOAST-2 (NCT05061550), a phase 2, randomised platform trial, tested novel perioperative treatments in patients with stage IIA–IIIB NSCLC.
By Lara McGrathNature AI
Read the full story
Originally published by Nature AI on Oct 25, 2026.
Comments
Sign in to join the discussion.